Dapagliflozin - wikidoc
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial - The
Dosage and administration of SGLT2 inhibitors according to renal... | Download Table
T2D Glycemic Control | Safety | FARXIGA® (dapagliflozin) 5 mg & 10 mg tablets | For HCPs
Xigduo XR Dosage/Direction for Use | MIMS Malaysia
Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study | BMJ Open Diabetes
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial | Drugs
Comparison of dapagliflozin plasma concentration time-profiles between... | Download Scientific Diagram
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus - Komoroski - 2009 - Clinical Pharmacology & Therapeutics - Wiley Online Library
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial - The Lancet Diabetes & Endocrinology
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FARXIGA safely and effec
Geometric mean AUC and C max from PBPK model simulations compared with... | Download Scientific Diagram
Pharmacokinetic parameters of DWP16001, dapagliflozin, and... | Download Scientific Diagram
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes | Journal of Medicinal Chemistry
Dapagliflozin for the Treatment of Type 2 Diabetes | Semantic Scholar
Dose-response effect of dapagliflozin on day 7 24-hours urinary glucose... | Download Scientific Diagram
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans | Drug Metabolism & Disposition
Forxiga 5 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc)
Forxiga Full Prescribing Information, Dosage & Side Effects | MIMS Malaysia
Dapagliflozin - wikidoc
Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes - Deborah Hinnen, 2015
Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, D | DDDT
Forxiga 10 mg Tablet - Uses, Dosage, Side Effects, Price, Composition | Practo
